Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

C

Canadian Retinal Trials Group

Status and phase

Unknown
Phase 3
Phase 2

Conditions

Age-Related Macular Degeneration

Treatments

Drug: Triamcinolone Acetonide

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00148551
01 (C03 - 0236)

Details and patient eligibility

About

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Full description

This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Enrollment

120 estimated patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Individuals with predominantly classic, subfoveal CNV secondary to AMD.
  • No previous PDT Treatment in study eye.

Exclusion criteria

  • CNV from conditions, other than AMD.
  • Other disease that could be responsible for decreased vision.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems